Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Net Revenue	$ 18,080	$ 18,682	$ 37,748	$ 34,806
Drug products
Disaggregation of Revenue [Line Items]
Net Revenue	65	547	130	768
Concentrates Products
Disaggregation of Revenue [Line Items]
Net Revenue	18,015	18,135	37,618	34,038
U.S.
Disaggregation of Revenue [Line Items]
Net Revenue	16,125	16,595	34,057	31,039
U.S. | Drug products
Disaggregation of Revenue [Line Items]
Net Revenue	0	209	0	368
U.S. | Concentrates Products
Disaggregation of Revenue [Line Items]
Net Revenue	16,125	16,386	34,057	30,671
Rest of World
Disaggregation of Revenue [Line Items]
Net Revenue	1,955	2,087	3,691	3,767
Rest of World | Drug products
Disaggregation of Revenue [Line Items]
Net Revenue	65	338	130	400
Rest of World | Concentrates Products
Disaggregation of Revenue [Line Items]
Net Revenue	1,890	1,749	3,561	3,367
Product Sales – Point-in-time | Drug product sales
Disaggregation of Revenue [Line Items]
Net Revenue	0	482	0	641
Product Sales – Point-in-time | Concentrates product sales
Disaggregation of Revenue [Line Items]
Net Revenue	18,015	17,655	36,146	33,082
Product Sales – Point-in-time | U.S. | Drug product sales
Disaggregation of Revenue [Line Items]
Net Revenue	0	209	0	368
Product Sales – Point-in-time | U.S. | Concentrates product sales
Disaggregation of Revenue [Line Items]
Net Revenue	16,125	15,906	32,585	29,715
Product Sales – Point-in-time | Rest of World | Drug product sales
Disaggregation of Revenue [Line Items]
Net Revenue	0	273	0	273
Product Sales – Point-in-time | Rest of World | Concentrates product sales
Disaggregation of Revenue [Line Items]
Net Revenue	1,890	1,749	3,561	3,367
License Fee – Over time | Drug license fee
Disaggregation of Revenue [Line Items]
Net Revenue	65	65	130	127
License Fee – Over time | Concentrates product license fee
Disaggregation of Revenue [Line Items]
Net Revenue	0	480	1,472	956
License Fee – Over time | U.S. | Drug license fee
Disaggregation of Revenue [Line Items]
Net Revenue	0	0	0	0
License Fee – Over time | U.S. | Concentrates product license fee
Disaggregation of Revenue [Line Items]
Net Revenue	0	480	1,472	956
License Fee – Over time | Rest of World | Drug license fee
Disaggregation of Revenue [Line Items]
Net Revenue	65	65	130	127
License Fee – Over time | Rest of World | Concentrates product license fee
Disaggregation of Revenue [Line Items]
Net Revenue	$ 0	$ 0	$ 0	$ 0